| Intensive lipid lowering in patients with rheumatoid arthritis and previous myocardial infarction: an explorative analysis from the incremental decrease in endpoints through aggressive lipid lowering (IDEAL) trial. | |
| | |
MedLine Citation:
|
PMID: 20884656 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
Objectives. Documentation on secondary prevention with statins in RA patients with coronary heart disease (CHD) is limited, despite the increased risk of CHD in RA. Our objective was to describe the effect of statin treatment on lipid levels and cardiovascular disease (CVD) events in patients with RA who participated in the incremental decrease in endpoints through aggressive lipid lowering (IDEAL) study. Methods. Patients with previous myocardial infarction (MI) were randomly assigned to atorvastatin 80 mg daily or simvastatin 20-40 mg daily and followed for 4.8 years. We focused on changes in lipid levels in the current exploratory analyses and used the composite secondary endpoint in the IDEAL study: any CVD event. Out of the 8888 patients in the IDEAL study, 87 had RA. Results. RA patients had significantly lower baseline levels of total- and low-density lipoprotein (LDL) cholesterol than patients without RA; 4.8 + 1.0 vs 5.1 + 1.0 (P = 0.023) and 2.9 + 0.9 vs 3.1 + 0.9 mmol/l (P = 0.034) for total cholesterol and LDL, respectively. The lipid reductions with either simvastatin or atorvastatin were comparable. Cardiovascular events occurred in 23/87 (26.4%) of the RA patients compared with 2523/8801 (28.7%; P = 0.70) in the general IDEAL population. The occurrence of these events was not related to the duration of RA, age, gender or treatment assignment. Conclusion. Patients with RA and previous MI had comparable lipid-lowering effect and similar rates of cardiovascular events as those without RA, although the RA patients had lower baseline cholesterol levels than patients without RA. |
| | |
Authors:
|
Anne G Semb; Ingar Holme; Tore K Kvien; Terje R Pedersen |
Related Documents
:
|
20659406 - Decreased levels of ccr3 in cd4+ lymphocytes of rheumatoid arthritis patients. 11791646 - Serum vascular endothelial growth factor in late rheumatoid arthritis. 14672886 - Bone loss in unclassified polyarthritis and early rheumatoid arthritis is better detect... 15355746 - Update on autoantibodies in rheumatoid arthritis. 19173016 - Continuous non-invasive arterial pressure technique improves patient monitoring during ... 11816706 - Increased brain natriuretic peptide as a marker for right ventricular dysfunction in ac... |
Publication Detail:
|
Type: Journal Article Date: 2010-09-30 |
Journal Detail:
|
Title: Rheumatology (Oxford, England) Volume: 50 ISSN: 1462-0332 ISO Abbreviation: Rheumatology (Oxford) Publication Date: 2011 Feb |
Date Detail:
|
Created Date: 2011-01-18 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 100883501 Medline TA: Rheumatology (Oxford) Country: England |
Other Details:
|
Languages: eng Pagination: 324-9 Citation Subset: AIM; IM |
Affiliation:
|
Department of Rheumatology, Diakonhjemmet Hospital, PO Box 23 Vinderen, NO-0319 Oslo, Norway. a-semb@diakonsyk.no. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Association of gastrointestinal involvement and depressive symptoms in patients with systemic sclero...
Next Document: Late-onset systemic sclerosis--a systematic survey of the EULAR scleroderma trials and research grou...